-+ 0.00%
-+ 0.00%
-+ 0.00%
MediciNova says US patent office allows ibudilast–anti-PD-1 combo claims for glioblastoma treatment
Share
Listen to the news
MediciNova says US patent office allows ibudilast–anti-PD-1 combo claims for glioblastoma treatment
  • MediciNova received a U.S. patent allowance covering MN-166 (ibudilast) combined with an anti-PD-1 immune checkpoint inhibitor for glioblastoma.
  • Patent terms extend to dosing and administration parameters; expected to expire no earlier than September 2042.
  • Expanded IP could support its combination-therapy strategy for MN-166 in oncology.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MediciNova Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606300800PRIMZONEFULLFEED9754084) on June 30, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending